3月7日 - ** 医疗设备制造商Dexcom DXCM.O股价在延时交易中下跌6.2%，至73美元
** 该公司称，在对其两家主要生产设施进行检查后， (link)，收到了美国食品和药物管理局（FDA）的警告信。
** 警告信包含了对 DXCM 位于加利福尼亚州圣迭戈和亚利桑那州梅萨的工厂的生产流程和质量管理系统的意见和发现的问题。
** 公司预计警告信不会对其生产能力或 2025 财年的销售前景造成实质性影响
** 2024 年，DXCM 下降 37.3
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.